LETTER TO THE EDITOR

PIGO deficiency: palmoplantar keratoderma and novel mutations

Marie-Anne Morren1, Jaak Jaeken2,9†, Gepke Visser3, Isabelle Salles4, Chris Van Geet2,5, NIHR BioResource6, Ilenia Simeoni6,7,10, Ernest Turro6,8,10 and Kathleen Freson5

Abstract

Background: Several genetic defects have been identified in the glycosylphosphatidylinositol (GPI) anchor synthesis, including mutations in PIGO encoding phosphatidylinositol glycan anchor biosynthesis class O protein. These defects constitute a subgroup of the congenital disorders of glycosylation (CDG). Seven patients from five families have been reported carrying variants in PIGO that cause an autosomal recessive syndrome characterised by dysmorphism, psychomotor disability, epilepsy and hyperphosphatasemia.

Methods: Whole exome sequencing was performed in a boy with dysmorphism, psychomotor disability, epilepsy, palmoplantar keratoderma, hyperphosphatasemia and platelet dysfunction without a clinical bleeding phenotype.

Results: Two novel variants in PIGO were detected. The missense variant encoding p. His871Pro was inherited from the boy’s father while the frameshift variant encoding p. Arg604ProfsTer40 was maternally inherited.

Conclusion: A boy with two novel PIGO variants is reported. The skin phenotype and platelet dysfunction in this patient have not been described in previously reported patients with PIGO deficiency but it is of course uncertain whether these are caused by this disorder. The literature on PIGO deficiency is reviewed.

Keywords: CDG, Congenital disorder(s) of glycosylation, Glycosylphosphatidylinositol, GPI, Hyperkeratosis, Hyperphosphatasemia, PIGO-CDG, Platelet dysfunction

Introduction

GPI anchors are a group of glycolipids with a glycan core, a phosphoethanolamine linker and a phospholipid tail. At least 150 human cell-surface proteins are post-translationally modified by GPI anchors at the carboxyl-terminus. These proteins are anchored to the outer leaflet of the plasma membrane via the phosphatidylinositol moiety. These GPI-anchored proteins include adhesion molecules, complement regulatory proteins, hydrolases, protease inhibitors and receptors. At least 26 genes are involved in the biosynthesis, protein-attachment and remodelling of mammalian GPI [1]. Genetic defects have been reported in 12 of these genes [2, 3]. They belong to subgroup 3 in the current classification of congenital disorders of glycosylation (CDG) [4]. One of them is a defect in phosphatidylinositol glycan anchor biosynthesis class O protein (PIGO). This enzyme, together with PIGF, catalyzes the attachment of ethanolamine phosphate to the third mannose of the three-mannosyl glycan core of GPI. Seven patients have been reported from five families with PIGO deficiency [5–8]. The present report is on a patient who expands the phenotypic spectrum of PIGO deficiency and carries novel mutations in the PIGO gene.

Patient report

The boy was born in 1994 from unrelated healthy parents from Afro-Caribbean ancestry after a 34 weeks pregnancy. He has a healthy sister. The family history was negative for keratotic disorders. Pregnancy was complicated by polyhydramnion from the fourth month. Delivery was normal. Birth weight was 2870 g, length unknown and head circumference 36.5 cm. At birth, he showed oedema, especially of the distal ends...
of the extremities, as well as dysmorphism: broad nasal
bridge, right preauricular tag, W-shaped upper lip,
relatively large mouth, fusion of upper medial incisors,
short neck, hypogenitalism and hypogonadism
(testicles not palpable), and hypoplastic toenails. At 6
weeks, a deep infantile hemangioma was noted on the
right upper thorax. At 4 months, he was operated for a
right inguinal hernia. He had focal epilepsy at the age
of 17 months, which changed to multifocal epilepsy
and was reasonably controlled with valproate. Both
motor and cognitive development were severely
disabled. He started to walk at 3.5 years (abnormal gait
with abduction of both feet), and said ‘mama’ and
‘papa’ at about 6 years.

On physical examination at 7 years, height was
123 cm (SDS 0.0), weight 25.5 kg (SDS 0.6), head cir-
cumference 56 cm (SDS 2.5). He smiled all the time.
Moderate obesity, convergent strabism and general
hyperlaxity were noted but no hypotonia. There was a
residual hemangioma on the right upper thorax. Dys-
morphism included malalignment of the upper medial
incisors (no fusion of the permanent teeth), a broad
nasal bridge, coarse ears, widely spaced nipples, mild
camptodactyly of the fingers, and small hands and feet
with short fingers and toes. There was a striking hyper-
keratosis of the foot soles and hand palms.

Physical examination at 11.5 years showed a height
of about 144 cm (SDS −0.7), weight 40 kg (SDS + 0.2) and
head circumference 57 cm (SDS + 1.9). He was still in-
continent for urine and faeces. The father mentioned
progress in language understanding but speech was ab-
sent and he made himself understandable with gestures.
He walked with his feet in 90 degrees abduction. There
was a thickened palmar and plantar skin, more
pronounced on pressure points, with a fine scaling
extending over the dorsal side of hands and feet includ-
ing the wrists and ankles. This thickened skin showed
accentuation of the skin lines, particularly on the wrists.
On the extensor side of elbows and knees the same
thickened skin was seen (Figs. 1 and 2). Vision and hear-
ing were clinically normal. There was no hepatospleno-
megalgy. Cardiopulmonary examination was normal. The
testes were small (nutshell size). Tendon reflexes were
brisk. He had a mild anal prolapse on pressure.

Laboratory investigation showed persistently in-
creased serum alkaline phosphatase (last control at
13 years: 5131 U/L; normal < 720) mainly due to
increased bone isozyme. There was also a decreased
serum apolipoprotein B (0.42 g/L; normal range
0.66–1.33) and LDL-cholesterol (37 mg/dL) with nor-
mal HDL cholesterol and triglycerides as well as a mild in-
crease of serum amylase (121 U/L; normal range 28–100)
and thyroid stimulating hormone (6.64 mIU/L; normal
range 0.27–4.20) but with normal free T4 and thyroxin-
binding globulin levels. Further routine blood and urine
chemistry as well as metabolic screening were normal in-
cluding serum calcium, phosphate, transaminases, creatine
kinase, lactate dehydrogenase, factor XI, ceruloplasmin,
cholinesterase, lipase, IgA, IgG, IgM and serum transferrin
isolectrofocusing.

The patient had no obvious clinical bleeding problem
and his Ivy bleeding time was normal as were all blood
cell counts. Repeated platelet function testing showed
decreased aggregation responses for ristocetin, ADP,
epinephrine and Horm collagen (Fig. 3a). A similar
multi - agonist platelet activation defect was detected
using a high-throughput ELISA that records dose re-
response activation of platelets where monoclonal
antibodies against P-selectin (CD62P) or αIIbβ3 and GPIbα were used to capture and detect platelet activation with ADP, U46619, TRAP and CRP [9] (Fig. 3b). In contrast, ATP secretion from dense granules after stimulation with 2 μg/ml Horm collagen was normal (4.1 and 4.8 μM; normal range of 2–7 μM). As mentioned above, the patient is on valproate therapy that is known to have slight effects on the arachidonic pathway of platelets. However, the observed broad platelet activation defect of this patient is not compatible with a defect in the arachidonic pathway. It was not possible to withdraw the drug for further platelet testing.

Radiological examination of the skeleton showed a thin cortex, triangular distal toe phalanges, scoliosis, wedge-shaped anterior flattening of the vertebrae, and a fusion anomaly of the arcus posterior of D3. MRI of the brain at 6 years showed enlarged lateral ventricles, a cavum septum pellucidum, a thin corpus callosum, and

Fig. 2 Keratoderma of the hands, foot soles and knees of the patient at 13 years

Fig. 3 Platelet function studies. a Platelet aggregation with Horm collagen (2 μg/ml), ADP (5 μM) and epinephrine (5 μg/ml) was reduced in the patient. b A high throughput ELISA was performed that records dose response activation of platelets with monoclonal antibodies against P-selectin (CD62P) or αIIbβ3 to detect platelet activation with ADP, U46619, TRAP and CRP at different concentrations.
minimal white matter lesions at the level of the posterior horns.

A skin biopsy at the elbow showed a “basket woven” hyperorthokeratosis with papillomatosis. Electronmicroscopy revealed clear vesicles but this might have been a technical artefact.

DNA from the patient was analysed by whole exome sequencing (WES) as part of the NIHR BRIDGE-Bleeding and Platelet Disorders study [10] and compound heterozygous (and X-linked) rare variants were found in 8 genes that included two previously unreported variants in the PIGO gene for phosphatidylinositol glycan anchor biosynthesis class O protein. Details on gene selection from the WES data is described in the supplementary data (Additional file 1). Interestingly, recessive PIGO variants cause hyperphosphatasemia with mental retardation syndrome 2 (MIM 614749), as found in the patient. The missense variant c.2612A>C (p.His871Pro) was absent from ExAC while the frameshift variant c.1810dupC (p.Arg604ProfsTer40) was present in ExAC at a minor allele frequency (MAF) of 0.0001 (0.0002 in non-Finnish Europeans). Sanger sequencing confirmed the variants in the child and the mother was the carrier of the variant encoding p.His871Pro. Different DNA variant scoring systems predict p.His871Pro as pathogenic with CADD score of 20, PolyPhen score of 0.836 (‘possibly damaging’), SIFT score of 5.44 (‘deleterious’) and GERP score of 5.44.

**Discussion**

To date, only 7 patients from 5 families have been described with PIGO deficiency (Table 1) [5–8]. Interestingly, they all carry the combination of a high impact variant with a missense variant in PIGO. Table 1 summarizes the clinical findings of the previously reported patients and our patient. All eight patients had a moderate or severe psychomotor disability as well as hyperphosphatasemia. The following symptoms were present in the majority of patients: epilepsy (6/8), facial dysmorphism (6/8), brachytelephalangy (5/8), nail hypoplasia (4/7), and anorectal abnormalities (5/6). A minority of patients showed various neurological, cardiac, urogenital and skeletal abnormalities. Novel features observed in our patient include palmoplantar keratoderma, extreme rotation of the feet, dental abnormalities and platelet dysfunction.

Cutaneous abnormalities have been reported in two other GPI anchor synthesis disorders. In patients with PIGA deficiency, dry scaling, ichthyosis-like and eczema-like lesions, pigmentation abnormalities, and linear plaque-like scales, including the feet, have been described [11]. More consistent skin lesions have been reported in patients with PIGL deficiency or CHIME syndrome (coloboma, congenital heart defects, early onset migratory ichthyosiform dermatosis, mental retardation, and ear anomalies, including conductive hearing loss). A diffuse, erythematous, pruritic, often migratory rash at or shortly after birth (sometimes even erythroderma) was present in all described cases. Thereafter, the skin becomes increasingly ichthyotic; primarily at the flexural surfaces [12, 13]. GPI anchoring plays a role in skin cells, particularly in keratinocytes. An epidermal-specific defect of GPI anchor in Pig-a null mice results in Harlequin ichthyosis-like features [14, 15]. In these mice, there was an impaired processing of profilaggrin to filaggrin, accompanied by a decreased activity of protein phosphatase 2A involved in this processing. Proteasin, one of the enzymes involved in filaggrin synthesis, is a GPI-anchored protein, and in mice its deficiency leads to a phenotype comparable to matriptase deficiency, a cause of autosomal recessive ichthyosis with hypotrichosis [15]. On the other hand, Tam et al. have shown that GPI-anchored proteins regulate transforming growth factor-beta signalling in human keratinocytes [16].

Platelet function has not been studied in GPI anchor disorders, probably because until now no patient showed a haematological phenotype. We studied it in our patient as part of the etiological work-up in unexplained psychomotor disability. A characteristic feature of PIGO deficiency (and of six other known GPI anchor synthesis defects, namely in PIGA, PIGV, PIGW, PGAP1, PGAP2 and PGAP3) is the increase of serum alkaline phosphatase (tissue nonspecific; liver/bone/kidney), while in PIGT deficiency serum alkaline phosphatase is decreased [17] (reminiscent of hereditary hypophosphatasia). Alkaline phosphatase testing may be helpful in the etiological work-up of patients with (syndromic or non-syndromic) intellectual disability, and the finding of increased or decreased levels of this enzyme should prompt a search for a GPI anchor defect.

Coagulation and platelet defects have been reported in different congenital disorders of glycosylation as important receptors and proteins for coagulation, platelet formation and function are regulated by glycosylation [18–25]. The importance of GPI-anchoring for platelet proteins is not well studied. It is known that GPI-anchored glycoproteins are absent or deficient in platelets from patients with paroxysmal nocturnal haemoglobinuria (PNH) [26]. PNH is an acquired stem cell disorder due to somatic variants in PIGA and causes an abnormal susceptibility of erythrocytes to complement induced lysis, resulting in episodes of intravascular haemolysis, haemoglobinuria and both thromboembolic events and bleeding complications. Platelets from PNH cases showed platelet hyporeactivity using in vitro assays possibly due to chronic hyperstimulation in the
| Age at publication | Gender | Psychomotor disability | Microcephaly | Epilepsy | Facial dysmorphism | Brachytelephalangy | Nail hypoplasia | Anorectal abnormalities | Hyperphosphatasemia | Other features | Mutations: cDNA/protein |
|-------------------|--------|------------------------|-------------|----------|------------------|------------------|---------------|-----------------------|------------------|--------------|---------------------|
| Krawitz et al. (pt A1) | Female | Severe | NA | - | Hypertelorism, wide-set eyes, long palpebral fissures, short nose, broad nasal bridge and tip, tented mouth | + | Fingers and toes | Anal stenosis | + | Growth retardation, broad halluces, vesicoureteral reflux | c.2869C > T/p.Leu957Phe |
| 15 years | | | | | | | | | | | |
| Krawitz et al. (pt A2) | Female | Moderate | NA | - | Hypertelorism, wide-set eyes, long palpebral fissures, short nose, broad nasal bridge and tip, tented mouth | + | Fingers and toes | Anal atresia with perineal fistula | | | |
| 12 years | | | | | | | | | | |
| Kuki et al. | Male | Severe | + | + | Facial asymmetry, hypertelorism, wide-set eyes, long palpebral fissures, short nose, broad nasal bridge and tip, tented mouth, large ears with fleshy and uplifted earlobes | + | | | | | |
| 9 years | | | | | | | | | | |
| Nakamura et al. (pt 1) | Female | Severe | + | + | Coarse face, hypertelorism, blepharophimosis, short nose, broad nasal bridge, L cleft lip, low-set ears | + | Hirschsprung disease | NA | | Growth retardation, L coronal synostosis, broad halluces, atial septal defect, peripheral pulmonary synostosis, enlarged supratentorial ventricular system | c.389C > A/p.Thr130Asn |
| 19 years | | | | | | | | | | |
| Nakamura et al. (pt 2) | Male | Severe | + | + | | | | | | | c.1288C > T/p.Gln430* |
| 6 months | | | | | | | | | | |
| Xue et al. | Female | Moderate/ severe | NA | - | High arched palate, tented mouth | + | | | | | c.458 T > C/p.Phe153Ser |
| 9 years | | | | | | | | | | |
| Present report | Male | Moderate | Not at birth | + | | | | | | | c.2612A > C/p.His871Pro |
| 22 years at present | | | | | | | | | | |

**NA** not available
circulation [27]. Though functional platelet defects have not been reported in the other patients with PIGO variants, we detected a multi-
agonist platelet defect in our patient as a subclinical phenotype. Further studies need to be undertaken to support these findings and
compare them with PNH.

Additional file

Additional file 1: Gene selection from WES data. (DOCX 105 kb)

Abbreviations

CDG: Congenital disorder(s) of glycosylation;
GI: Glycosylphosphatidylinositol; PIGO: Phosphatidylinositol glycan anchor
biosynthesis class O protein; PNH: Paroxysmal nocturnal hemoglobinuria

Acknowledgements

This study makes use of whole genome sequencing data and analysis approaches generated by the NIHR Bioresource - Rare Disease BRIDGE

Consortium. The NIHR Bioresource - Rare Diseases is funded by the National Institute for Health Research of England (NIHR, www.nihr.ac.uk; award
number RG56966).

Funding

KF is supported by the Fund for Scientific Research-Flanders (FWO-Vlaanderen,
Belgium, G0B1713N) and by the Research Council of the University of Leuven
(BOF-KU Leuven, Belgium, OT/14/098).

Availability of data and material

Not applicable.

Authors’ contributions

MAM and JJ conceived and designed the study. Genetic data were
generated by NIHR BioResource and ISa, and analyzed by ET and KF. MAM, JJ,
GV, ISa, CVG, and KF wrote the paper. All authors reviewed the compiled
manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Written consent for publication was provided by the parents, whom we
thank for the help.

Ethics approval and consent to participate

The Institutional Review Board of the University Hospital Gasthuisberg
Leuven approved this study.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.

Author details

1 Departments of Dermatology, University of Leuven, Leuven, Belgium.
2 Pediatrics, University of Leuven, Leuven, Belgium. 3 Department of Pediatrics,
Wilhelmina Children’s Hospital, Utrecht, The Netherlands. 4 Centre for
Hematology, Imperial College, London, UK. 5 Department of Cardiovascular
Sciences, Center for Molecular and Vascular Biology, University of Leuven,
Leuven, Belgium. 6NHS Blood and Transplant, Cambridge Biomedical
Campus, Cambridge, UK. 7 Department of Haematology, University of
Cambridge, Cambridge Biomedical Campus, Cambridge, UK. 8 Medical
Research Council Biostatistics Unit, Cambridge Institute of Public Health,
Cambridge Biomedical Campus, Cambridge, UK. 9 Department of Pediatrics,
Center for Metabolic Diseases, University Hospital Gasthuisberg, Herestraat
49, BE 3000 Leuven, Belgium. 10NIHR Bioresource - Rare Diseases, Cambridge
University Hospitals, Cambridge Biomedical Campus, Cambridge, UK.

Received: 31 December 2016 Accepted: 15 May 2017
Published online: 25 May 2017

References

1. Fujita M, Kinoshita T. GPI-anchor remodelling: potential functions of
GPI-anchors in intracellular trafficking and membrane dynamics. Biochim
Biophys Acta. 1821;2012:1050–8.
2. Kinoshita T. Biosynthesis and deficiencies of glycosylphosphatidylinositol.
Proc Jpn Acad Ser B. 2014;90:130–43.
3. Ng BG, Freeze HH. Human genetic disorders involving
glycosylphosphatidylinositol (GPI) anchors and glycosphingolipids. J Inherit
Metab Dis. 2015;38:171–8.
4. Jaeken J, Henret T, Matthias G, Freeze HH. CDG nomenclature: time for a
change! Biochim Biophys Acta. 2009;1792:825–6.
5. Kwiatz PM, Murakami Y, Hecht J, et al. Mutations in PIGO, a member of the
GPI-anchor synthesis pathway, cause hyperphosphatasa with mental
 retardation. Am J Hum Genet. 2012;91:146–51.
6. Kuki I, Takahashi Y, Okazaki S, et al. Vitamin B6-responsive epilepsy due to
inherited GPI deficiency. Neurology. 2013;81:1467–9.
7. Nakamura K, Osaka H, Murakami Y, et al. PIGO mutations in intractable
epilepsy and severe developmental delay with mild elevation of alkaline
phosphatase levels. Epilepsia. 2014;55:e13–7.
8. Xue J, Li H, Zhang Y, Yang Z. Clinical and genetic analysis of two Chinese
infants with Mabry syndrome. Brain Dev. 2016;38:807–18.
9. Salles I, Broos K, Fontayne A, et al. Development of a high-throughput ELISA
 assay for platelet function testing using platelet-rich plasma or whole blood.
Thromb Haemost. 2010;104:392–401.
10. Westbury SK, Turro E, Greene D, et al. Human phenotype ontology
 annotation and cluster analysis to unravel genetic defects in 707 cases with
unexplained bleeding and platelet disorders. Genome Med. 2015;7:36. doi:
10.1186/s13073-015-0151-5.
11. Swoboda KJ, Margraf RL, Carey JC, et al. A novel germline PIGA mutation in
Ferro-Cerebro-Gutaneous syndrome: a neurodegenerative X-linked epileptic
encephalopathy with systemic iron overload. Am J Med Genet A.
2014;164A:17–28.
12. Ng BG, Hackmann K, Jones MA, et al. Mutations in the
glycosylphosphatidylinositol gene PIGL cause CHIME syndrome. Am J Hum
Genet. 2012;90:685–8.
13. Tinscher S, Anton-Lamprecht I, Albrecht-Nebe H, Audring H, Zurich
neuroectodermal syndromemigratory ichthyosiform dermatosis, coloboma
and other abnormalities. Pediatr Dermatol. 1996;13:363–71.
14. Hara-Chikuma M, Takeda J, Tarutani M, et al. Epidermal-specific defect of GPI
anchor in Pig-a null mice results in harlequin ichthyosis-like features. J
Invest Dermatol. 2004;123:464–9.
15. Ovaere P, Lippens S, Vandenberghe P, Declercq W. The emerging roles of
severe protease cascades in the epidermis. Trends Biochem Sci.
2009;34:453–63.
16. Tam BY, Finnson KW, Philip A. Glycosylphosphatidylinositol-anchored
proteins regulate transforming growth factor-beta signalling in human
keratinocytes. J Biol Chem. 2003;278:49610–7.
17. Nakashima M, Kashi H, Murakami Y, et al. Novel compound heterozygous
PKG7 mutations caused multiple congenital anomalies-hypotonia-seizures
 syndrome 3. Neurogenetics. 2014;15:193–200.
18. Van Geet C, Jaeken J, Freson K, et al. Congenital disorders of glycosylation
type Ia and Iia are associated with different primary hemostatic
complications. J Inherit Metab Dis. 2001;24:777–92.
19. de la Forina-Barrio ME, DI Michele M, Lozano ML, et al. Proteomic analysis
of platelet N-glycoprotein from PPM2-CDG patients. Thromb Res.
2014;133:412–17.
20. Noelle V, Knueper M, Pulzer F, et al. Unusual presentation of congenital
disorder of glycosylation type 1a: congenital persistent
thrombocytopenia, hypertrophic cardiomyopathy and hydrops-like
aspect due to marked peripheral oedema. Eur J Pediatr. 2005;164:233–6.
21. Jones C, Denecke J, Sträter R, et al. A novel type of
macrothrombocytopenia associated with a defect in α2,3-sialylation. Am
J Pathol. 2011;179:1969–77.
22. Wang Y, Jobe SM, Ding X, et al. Platelet biogenesis and function require
mature thrombospondin-1 for platelet production. Blood. 2014;123:2532–40.
23. Bartholomäi K, Bertram H, Hohlin D, et al. A novel type of
macrothrombocytopenia associated with a defect in α2,3-sialylation. Am
J Pathol. 2011;179:1969–77.
24. Wang Y, Jobe SM, Ding X, et al. Platelet biogenesis and function require
correct protein O-glycosylation. Proc Natl Acad Sci U S A. 2012;109:16143–8.
25. Badiou J, Kurdi M, Legendre P, et al. In vivo analysis of the role of
O-glycosylations of von Willbrand factor. PLoS One. 2012;7:e37508.
24. Alexander WS, Viney EM, Zhang JG, et al. Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 gene. Proc Natl Acad Sci U S A. 2006;103:16442–7.

25. O'Donnell SR, Kay CS. Effects of endothelin receptor selective antagonists, BQ-123 and BQ-788, on IRL 1620 and endothelin 1 responses of airway and vascular preparations from rats. Pulm Pharmacol. 1995;8:11–9.

26. Maciejewski JP, Young NS, Yu M, Anderson SM, Sloand EM. Analysis of the expression of glycosylphosphatidylinositol anchored proteins on platelets from patients with paroxysmal nocturnal hemoglobinuria. Thromb Res. 1996;83:433–47.

27. Grünewald M, Grünewald A, Schmid, et al. The platelet function defect of paroxysmal nocturnal hemoglobinuria. Platelets. 2004;15:145–54.